Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

Michael Groll, Celia R Berkers, Hidde L Ploegh, Huib Ovaa

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The dipeptide boronic acid bortezomib, also termed VELCADE, is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored. We determined the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites. This structure should enable the rational design of new boronic acid derivatives with improved affinities and specificities for individual active subunits.

Original languageEnglish
Pages (from-to)451-6
Number of pages6
JournalStructure
Volume14
Issue number3
DOIs
Publication statusPublished - 2006
Externally publishedYes

Keywords

  • Animals
  • Antineoplastic Agents
  • Boronic Acids
  • Bortezomib
  • Catalytic Domain
  • Crystallization
  • Leucine
  • Mammals
  • Models, Molecular
  • Peptides
  • Phenylalanine
  • Proteasome Endopeptidase Complex
  • Protein Structure, Quaternary
  • Pyrazinamide
  • Pyrazines
  • Structure-Activity Relationship
  • Substrate Specificity
  • Yeasts

Fingerprint

Dive into the research topics of 'Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome'. Together they form a unique fingerprint.

Cite this